These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16367926)

  • 1. SUCI02 inhibits the erbB-2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G1 phase in breast cancer cells.
    Zhu XF; Wang JS; Cai LL; Zeng YX; Yang D
    Cancer Sci; 2006 Jan; 97(1):84-9. PubMed ID: 16367926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [SUCI02 inhibits HER-2/neu receptor tyrosine kinase phosphorylation and growth of HER-2/neu-overexpressing breast cancer cells].
    Zhu XF; Liu ZC; Xie BF; Cai LL; Yang DJ
    Ai Zheng; 2003 Aug; 22(8):790-4. PubMed ID: 12917021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ON-III inhibits erbB-2 tyrosine kinase receptor signal pathway and triggers apoptosis through induction of Bim in breast cancer cells.
    Li DD; Wu XQ; Tang J; Wei XY; Zhu XF
    Cancer Biol Ther; 2009 Apr; 8(8):739-43. PubMed ID: 19242112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
    D'Alessio A; De Luca A; Maiello MR; Lamura L; Rachiglio AM; Napolitano M; Gallo M; Normanno N
    Breast Cancer Res Treat; 2010 Sep; 123(2):387-96. PubMed ID: 19946741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
    Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Houttuyninum, an active constituent of Chinese herbal medicine, inhibits phosphorylation of HER2/neu receptor tyrosine kinase and the tumor growth of HER2/neu-overexpressing cancer cells.
    Zhou NN; Tang J; Chen WD; Feng GK; Xie BF; Liu ZC; Yang D; Zhu XF
    Life Sci; 2012 May; 90(19-20):770-5. PubMed ID: 22525372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).
    Djerf EA; Trinks C; Abdiu A; Thunell LK; Hallbeck AL; Walz TM
    Melanoma Res; 2009 Jun; 19(3):156-66. PubMed ID: 19434003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
    Lenferink AE; Busse D; Flanagan WM; Yakes FM; Arteaga CL
    Cancer Res; 2001 Sep; 61(17):6583-91. PubMed ID: 11522658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells.
    Barbacci EG; Pustilnik LR; Rossi AM; Emerson E; Miller PE; Boscoe BP; Cox ED; Iwata KK; Jani JP; Provoncha K; Kath JC; Liu Z; Moyer JD
    Cancer Res; 2003 Aug; 63(15):4450-9. PubMed ID: 12907618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
    Rusnak DW; Lackey K; Affleck K; Wood ER; Alligood KJ; Rhodes N; Keith BR; Murray DM; Knight WB; Mullin RJ; Gilmer TM
    Mol Cancer Ther; 2001 Dec; 1(2):85-94. PubMed ID: 12467226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
    Chen J; Kinoshita T; Sukbuntherng J; Chang BY; Elias L
    Mol Cancer Ther; 2016 Dec; 15(12):2835-2844. PubMed ID: 27678331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network.
    Weingaertner IR; Koutnik S; Ammer H
    PLoS One; 2013; 8(1):e53510. PubMed ID: 23308242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
    Normanno N; Campiglio M; De LA; Somenzi G; Maiello M; Ciardiello F; Gianni L; Salomon DS; Menard S
    Ann Oncol; 2002 Jan; 13(1):65-72. PubMed ID: 11863114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
    Corkery B; Crown J; Clynes M; O'Donovan N
    Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells.
    Zhu XF; Liu ZC; Xie BF; Li ZM; Feng GK; Yang D; Zeng YX
    Cancer Lett; 2001 Aug; 169(1):27-32. PubMed ID: 11410322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells.
    Tian C; Ding P; Yuan Z; Li H; Zhao Y; Sun L; Guo Q; Wang Z; Sun L; Zhang L; Jiang Z
    Apoptosis; 2015 Dec; 20(12):1599-612. PubMed ID: 26437915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
    Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
    Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.